Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 830 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pain, Cancer Clear all

Conditions: Pancreatic Cancer Pain
Interventions: EUS; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Burning Pain, Impaired Balance, Malignant Ovarian Neoplasm, Numbness, Peripheral Neuropathy, Pain, Acute, Tingling
Interventions: Diode Laser fiber type Selective Stimulator (DLss); Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Breast Cancer Female
Interventions: Bupivacaine Hydrochloride, Placebo Drug, Pulsed Electromagnetic Field (PEMF) Device, Placebo Device, Ropivacaine Hydrochloride; Drug · Other · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Dermatologic Complications, Malignant Neoplasm, Pain
Interventions: menadione topical lotion, placebo, questionnaire administration, management of therapy complications; Drug · Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: Phoenix, Arizona • Rochester, Minnesota

Conditions: Breast Cancer, Arthralgia
Interventions: Exercising block; Behavioral
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Neuropathic Pain, Cancer Treatment
Interventions: Green Tea Leaf Extract Decaffeinated, Placebo Control; Dietary Supplement · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Opioid-Induced Constipation
Interventions: methylnaltrexone, placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 4
States / cities: Laguna Hills, California • Lancaster, California • Flat Rock, North Carolina + 1 more

Conditions: Breast Cancer, Pain
Interventions: acupuncture therapy, sham acupuncture; Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 47
States / cities: Antioch, California • Fremont, California • Los Angeles, California + 36 more

Conditions: Pain, Colorectal Adenomas, Colorectal Cancer
Interventions: Air Insufflation method., Water Immersion method., Water Exchange method.; Other
Lead sponsor: Presidio Ospedaliero Santa Barbara; Other
Eligibility: 50 Years to 70 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pain, Chronic, Dementia, Mild, Mobility Limitation, Physical Disability, Osteo Arthritis Knee, Mild Cognitive Impairment
Interventions: Tailored Physical Activity Program; Behavioral
Lead sponsor: Drexel University; Other
Eligibility: 60 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Intractable Pain, Palliative Care
Interventions: Intrathecal Resiniferatoxin; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Moderate-to-severe Chronic Noncancer Pain
Interventions: Oxycodone extended-release; Drug
Lead sponsor: Egalet Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 39
States / cities: Huntsville, Alabama • Tucson, Arizona • Jacksonville, Florida + 35 more

Conditions: Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain, Breast Cancer
Interventions: Hydroxychloroquine Sulfate (HCQ); Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Myasthenia Gravis, Guillain-Barre Syndrome, Multiple Sclerosis, Seizures, Parkinsonism, Meningitis, Encephalitis, Headache, Vestibular Disorder, Spondylosis, Normal Pressure Hydrocephalus
Interventions: Current standard discharge educational intervention, Personalized discharge educational intervention; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 95 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Breast Cancer, Chronic Pain
Interventions: No intervention; Other
Lead sponsor: University of Florida; Other
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Malignant Neoplasm
Interventions: Best Practice, Laboratory Biomarker Analysis, Oculus Rift Headset, Questionnaire Administration; Other · Device
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Peripheral Neuropathy, Antineoplastic Combined Chemotherapy Protocols
Interventions: Cesamet™ (nabilone); Drug
Lead sponsor: NEMA Research, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Aventura, Florida • Naples, Florida

Conditions: Prostate Cancer
Interventions: Lidocaine; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Aromatase Inhibitor, Musculoskeletal Symptoms, Postmenopausal Breast Cancer Survivors
Interventions: APA, Sham APA control, Education control; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Postmenopausal, Breast Cancer
Interventions: Acupressure; Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Cancer, Breast Cancer Female
Interventions: PVB Protocol, PECS-1, Serratus; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Questionnaires, Yoga Classes; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Arthralgia, Breast Neoplasms
Interventions: Omega-3 Fatty Acid, Placebo; Dietary Supplement · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Duarte, California • Cleveland, Ohio • Columbus, Ohio

Conditions: Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer
Interventions: custirsen sodium, isotonic, 0.9% sodium chloride, docetaxel, cabazitaxel, prednisone; Drug
Lead sponsor: Achieve Life Sciences; Industry
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 20
States / cities: La Verne, California • Fort Lauderdale, Florida • Tampa, Florida + 17 more

Search by objective public record fields.

EUS Guided Celiac Neurolysis

Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN

PEMF and PEC Blocks in Mastectomy Reconstruction Patients

Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab

Exercise Intervention in Breast Cancer Patients With Treatment-Induced Arthralgia

Daily, Encapsulated, Green Tea Extract to Mitigate Neuropathic Pain in Patients With Established Cancer-Associated Neuropathic Pain

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer

A Comparison of Air Insufflation, Water Immersion and Water Exchange Colonoscopy in CRC Screening

Developing a Nonpharmacological Pain Intervention for Community-dwelling Older Adults With Dementia

Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

Pilot Study of Hydroxychloroquine for the Treatment of AIMSS

Neurology Inpatient Clinical Education Trial

Persistent Post-Surgical Pain in Women With BrCA

Virtual Reality in Reducing Pain and Anxiety in Cancer Participants Undergoing Painful Procedures

Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy

Study On Lidocaine Vs. Placebo Pain Control During Transrectal Ultrasound Guided Prostate Biopsy

Auricular Point Acupressure to Self-Manage Chronic Pain or Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors: Effectiveness and Scientific Underpinnings

Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer

Study of Nerve Block Pain Management in Patients Undergoing a Double Mastectomy With Immediate Reconstruction

Yoga for Aromatase Inhibitor-associated Joint Pain

Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)